Sensitivity analysis
| Analysis . | Patients with AHA (N = 69) . | Controls (N = 69) . | OR (95% CI) . | P . |
|---|---|---|---|---|
| All patients, n (%) | 44 (64) | 21 (30) | 4.02 (2.02-8.01) | .0002 |
| Autoimmune disorders excluded, n (%) | 37 (65) | 21 (31) | 4.14 (1.93-8.99) | .0002 |
| Malignant disorders excluded, n (%) | 37 (61) | 17 (29) | 3.81 (1.73-7.79) | .0005 |
| Pregnancy excluded, n (%) | 41 (64) | 21 (31) | 3.99 (1.94-8.20) | .0002 |
| IST at baseline excluded, n (%) | 39 (60) | 18 (28) | 3.92 (1.87-8.29) | .0004 |
| Analysis . | Patients with AHA (N = 69) . | Controls (N = 69) . | OR (95% CI) . | P . |
|---|---|---|---|---|
| All patients, n (%) | 44 (64) | 21 (30) | 4.02 (2.02-8.01) | .0002 |
| Autoimmune disorders excluded, n (%) | 37 (65) | 21 (31) | 4.14 (1.93-8.99) | .0002 |
| Malignant disorders excluded, n (%) | 37 (61) | 17 (29) | 3.81 (1.73-7.79) | .0005 |
| Pregnancy excluded, n (%) | 41 (64) | 21 (31) | 3.99 (1.94-8.20) | .0002 |
| IST at baseline excluded, n (%) | 39 (60) | 18 (28) | 3.92 (1.87-8.29) | .0004 |
Numbers, proportions, and OR for ANA positivity in patients with AHA and controls (entire cohort or excluding various underlying disorders or baseline medication).